Trial Profile
Pilot randomised controlled trial of SITAgliptin for Depressive Symptoms in type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Depression; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SITADS Study
- 01 Oct 2021 Results published in the Psychosomatic Medicine
- 05 Dec 2019 Status changed from recruiting to completed.
- 19 Jun 2019 Planned number of patients changed from 60 to 44.